CA
NZ
UK
AU
IND
US
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) reported earnings per share of $0.30 for the recent quarter, exactly aligning with analyst consensus. The result reaffirmed the firm’s financial discipline and set a steady foundation for its ongoing development programs. With earnings on target, the market’s …
Relmada Therapeutics (NASDAQ: RLMD) is invigorating its executive team by appointing Bipin Dalmia as Chief Business Officer. Dalmia's extensive background in non-muscle invasive bladder cancer (NMIBC) and corporate strategy comes at a critical juncture for the company. His leadership is anticipated to significantly influence …
The anticipated changes to Medicare's drug pricing program are set to have repercussions that may affect the financial environment for healthcare companies, including COLRF. As the government moves forward with alterations aimed at addressing drug affordability, experts predict that more seniors may be tempted …
Alkermes plc reported earnings per share of $0.00, exceeding a consensus estimate of $-0.02. Despite a strong year-to-date growth of 78.1% in share value, the stock fell 4.53% following the quarterly update, illustrating investor caution amidst ongoing market fluctuations and insider activity.Key HighlightsAlkermes reported …
Bicara Therapeutics Inc. This transition in leadership is important for the company as it seeks to enhance its focus on commercialization strategies, particularly as it advances its lead candidate, ficerafusp alfa, a bifunctional therapy targeting solid tumors. This board shift marks a significant moment …
Boston Scientific Corporation (BSX) has launched a comprehensive restructuring plan estimated to generate annual pre-tax savings of approximately $500 million. While the initiative will involve job cuts, the company aims to create new positions in growth areas, presenting a mixed outlook for investors amid …
Incyte Corporation achieved second-quarter earnings of $3.09 per share, surpassing consensus expectations of $2.14, amid a 38% revenue increase to $1.67 billion. This strong performance, driven by core product growth, positions the company favorably ahead of several upcoming clinical data releases.Key HighlightsIncyte reported Q2 …
Jupiter Neurosciences (NASDAQ: JUNS) sold 11,470,000 common shares for about $3.6 million, pricing each at 97% of the three‑day VWAP. The transaction occurs as the stock trades at $0.10, with a market capitalisation of $8 million. The cash infusion provides immediate funding, yet the …
Parallel has suspended operations at two of its facilities, resulting in a significant reduction of its workforce by 211 employees. The closures primarily affect its Wimauma and Lakeland sites in Florida, where various production and cultivation roles have been eliminated. Employees affected by these …
Revenue in the period measured $865.8 million, essentially unchanged from the prior year after normalizing for supplemental payment timing, while same‑facility patient days nudged up 0.8% and revenue per patient day fell 0.8%.
Please wait processing your request...